Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC

September 12th 2021

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

MSI-H/dMMR Prostate Cancer Linked With Response to Checkpoint Blockade

September 11th 2021

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Prognostic Risk Group, Receipt of Subsequent Therapies May Impact OS in mCRPC Receiving Lutetium 177

September 11th 2021

Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies may impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Relugolix Induces Similar Rates of Castration Resistance–Free Survival Vs Leuprolide in Advanced Prostate Cancer

September 11th 2021

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer

September 11th 2021

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

Dr. Tewari on the Benefits of Robotic Radical Prostatectom​y​ in Prostate Cancer

September 10th 2021

Ashutosh K. Tewari, MD, discusses the benefits of robotic radical prostatectom​y in prostate cancer.

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

September 10th 2021

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCC

September 10th 2021

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

RWE Demonstrates Robust PSA Response and Treatment Adherence of Apalutamide in CRPC

September 10th 2021

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

BMI Is a Significant Predictor for Survival in mCRPC

September 10th 2021

Obese men with metastatic castration-resistant prostate cancer have better disease-specific and overall survival than overweight or normal weight patients.

NICE Recommends Apalutamide Plus ADT for Prostate Cancer

September 9th 2021

The United Kingdom’s National Institute of Health and Care Excellence has recommended apalutamide for use in combination with androgen deprivation therapy in patients with high-risk hormone-relapsed nonmetastatic prostate cancer and in those with hormone-sensitive metastatic prostate cancer if docetaxel is not suitable or cannot be tolerated.

Triple Therapy Approaches for mCSPC

September 7th 2021

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

ADT Monotherapy in mCSPC

September 7th 2021

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 1st 2021

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate Cancer

August 31st 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

Black Men 97% Less Likely Than White Men to Receive Prostatectomy During COVID-19 Pandemic

August 31st 2021

During the height of the COVID-19 pandemic, Black patients were significantly less likely to undergo prostate cancer surgery compared with White patients, highlighting potential systemic inequities in care across medical specialties, and providing further rationale to recognize and the unintended diversion in cancer care due to the pandemic.

PARP Inhibitors Play Key Role in Prostate Cancer Paradigm, as Hunt for Biomarkers Continues

August 31st 2021

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

August 31st 2021

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Dr. Dorff on Biomarkers of Response to PARP Inhibitors in Prostate Cancer

August 30th 2021

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPC

August 30th 2021

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

NEXT PAGE
PREVIOUS PAGE